Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.55 |
| ▸ | BRD4 | O60885 | 6/20 | 0.55 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | IL1B | P01584 | 1/20 | 0.50 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.50 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30169800 | 0.98 | CRBN (0.55) | CRBNBRD4MAP1LC3BTNFIL1B | |
| SCHEMBL29091179 | 0.97 | CRBN (0.54) | CRBNBRD4MAP1LC3B | |
| SCHEMBL30595224 | 0.97 | CRBN (0.54) | CRBNBRD4MAP1LC3B | |
| SCHEMBL30575188 | 0.97 | CRBN (0.54) | CRBNBRD4MAP1LC3B | |
| SCHEMBL29091122 | 0.97 | CRBN (0.54) | CRBNBRD4MAP1LC3B | |
| SCHEMBL28652486 | 0.92 | CRBN (0.54) | CRBNBRD4MAP1LC3BTNFIL1B | |
| SCHEMBL26321010 | 0.90 | CRBN (0.64) | CRBNBRD4MAP1LC3BTNFIL1B | |
| SCHEMBL22580836 | 0.90 | CRBN (0.58) | CRBNBRD4MAP1LC3BDDB1 | |
| SCHEMBL24818155 | 0.89 | STAT3 (0.55) | CRBNBRD4MAP1LC3BTNFIL1B | |
| SCHEMBL30369513 | 0.89 | STAT3 (0.55) | CRBNBRD4MAP1LC3BTNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639343-B2 | Compounds targeting and degrading BCR-ABL protein and its antitumor application | SHANGHAITECH UNIVERSITY (CN) | 2023-05-02 | — | — | US | disclosed |
| US-11639343-B2 | Compounds targeting and degrading BCR-ABL protein and its antitumor application | SHANGHAITECH UNIVERSITY (CN) | 2023-05-02 | — | — | US | disclosed |
| US-20200407342-A1 | COMPOUNDS TARGETING AND DEGRADING BCR-ABL PROTEIN AND ITS ANTITUMOR APPLICATION | SHANGHAITECH UNIVERSITY (CN) | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407342-A1 | COMPOUNDS TARGETING AND DEGRADING BCR-ABL PROTEIN AND ITS ANTITUMOR APPLICATION | CRBN, VHL, CBL | CRBN 1/4885BRD4 1105/4885MAP1LC3B 905/4885 |
| US-11639343-B2 | Compounds targeting and degrading BCR-ABL protein and its antitumor application | CRBN, VHL, CBL | CRBN 1/4885BRD4 1105/4885MAP1LC3B 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.